A systematic review of modafinil: Potential clinical uses and mechanisms of action

Journal of Clinical Psychiatry

Volumn 67, Issue 4, 2006, Pages 554-566

  Ballon, Jacob S ^a,b   Feifel, David ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA 1A ADRENERGIC RECEPTOR; DOPAMINE; GLUTAMIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; MODAFINIL; OREXIN;

ANXIETY DISORDER; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; BIPOLAR DEPRESSION; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; COCAINE DEPENDENCE; DEPRESSION; DIARRHEA; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HUMAN; INSOMNIA; MULTIPLE SCLEROSIS; NARCOLEPSY; NAUSEA; NERVOUSNESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REM SLEEP; REVIEW; SCHIZOPHRENIA; SHIFT WORKER; SIDE EFFECT; SLEEP APNEA SYNDROME; SLEEP DISORDER; SYSTEMATIC REVIEW; WAKEFULNESS;

EID: 33646768643     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0406     Document Type: Review

References (146)

1. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998;43:88-97
2. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175
3. Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997;49:444-451
4. Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep 1994;17(suppl 8):S107-112
5. Chakravorty SS, Rye DB. Narcolepsy in the older adult: epidemiology, diagnosis and management. Drugs Aging 2003;20:361-376
6. Billiard M. Modafinil: pharmacology and therapeutic perspectives [in French]. Rev Neurol (Paris) 2003;159:122-125
7. Scammell TE, Matheson J. Modafinil: a novel stimulant for the treatment of narcolepsy. Expert Opin Investig Drags 1998;7:99-112
8. Modafinil for narcolepsy. Med Lett Drugs Ther 1999;41:30-31
9. Czeisler CA, Walsh JK, Roth T, et al. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005;353:476-486
10. Keating GM, Raffin MJ. Modafinil: a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder. CNS Drugs 2005;19:785-803
11. Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005;28:464-471
12. Schwartz JR, Hirshkowitz M, Erman MK, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea: a 12-week, open-label study. Chest 2003;124:2192-2199
13. Pack AI, Black JE, Schwartz JR, et al. Modafinil as adjunct therapy for daytime sleepiness in obstructive sleep apnea. Am J Respir Crit Care Med 2001;164:1675-1681
14. Kingshott RN, Vennelle M, Coleman EL, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual excessive daytime sleepiness in the sleep apnea/hypopnea syndrome. Am J Respir Crit Care Med 2001;163:918-923
15. US Food and Drug Administration, Provigil Consumer Information. Available at: http://www.fda.gov/cder/consumerinfo/druginfo/provigil.htm. Accessibility verified March 2, 2006
16. Simon P, Hemet C, Ramassamy C, et al. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 1995;5:509-514
17. Teitelman E. Off-label uses of modafinil [letter]. Am J Psychiatry 2001;158:1341
18. Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992;591:319-326
19. Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001;21:1787-1794
20. Miller MC. What are the dangers of methamphetamine? Harv Ment Health Lett 2005;22:8
21. 1B- adrenoceptors in modafinil-induced behavioral activity. Synapse 2002;46:269-270
22. Stone EA, Lin Y, Suckow RF, et al. Stress-induced subsensitivity to modafinil and its prevention by corticosteroids. Pharmacol Biochem Behav 2002;73:971-978
23. Shelton J, Nishino S, Vaught J, et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995;18:817-826
24. Dragunow M, Faull R. The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods 1989;29:261-265
25. Lin JS, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 1996;93:14128-14133
26. Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8628
27. Engber TM, Koury EJ, Dennis SA, et al. Differential patterns of regional c-Fos induction in the rat brain by amphetamine and the novel wakefulness-promoting agent modafinil. Neurosci Lett 1998;241:95-98
28. Ferraro L, Antonelli T, O'Connor WT, et al. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake Mockers. Biol Psychiatry 1997;42:1181-1183
29. Jaffe JH, Ling W, Rawson RA. Substance-related disorders. In: Sadock BJ, Sadock VA, eds. Kaplan and Sadock's Comprehensive Textbook of Psychiatry, vol 1, pt 2. 8th ed. Philadelphia, Pa: Lippincott, Williams & Wilkins; 2005:1195
30. Ferraro L, Tanganelli S, O'Connor WT, et al. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996;306:33-39
31. Ferraro L, Tanganelli S, O'Connor WT, et al. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 1996;220:5-8
32. Ferraro L, Antonelli T, O'Connor WT, et al. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 1997;8:2883-2887
33. Perez de la Mora M, Aguilar-Garcia A, Ramon-Frias T, et al. Effects of the vigilance promoting drug modafinil on the synthesis of GABA and glutamate in slices of rat hypothalamus. Neurosci Lett 1999;259:181-185
34. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999;98:365-376
35. Li Y, Gao XB, Sakurai T, et al. Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. Neuron 2002;36:1169-1181
36. Ko EM, Estabrooke IV, McCarthy M. et al. Wake-related activity of tuberomammillary neurons in rats. Brain Res 2003;992:220-226
37. Huang ZL, Qu WM, Li WD, et al. Arousal effect of orexin A depends on activation of the histaminergic system. Proc Natl Acad Sci U S A 2001;98:9965-9970
38. Ishizuka T, Sakamoto Y, Sakurai T, et al. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 2003;339:143-146
39. Robertson P, DeCory HH, Madan A, et al. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000;28:664-671
40. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42:123-137
41. Clemons WE, Makela E, Young J. Concomitant use of modafinil and tranylcypromine in a patient with narcolepsy: a case report. Sleep Med 2004;5:509-511
42. Ashton AK. Modafinil augmentation of phenelzine for residual fatigue in dysthymia [letter]. Am J Psychiatry 2004;161:1716-1717
43. Buguet A, Montmayeur A, Pigeau R, et al. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work, 2: effects on two nights of recovery sleep. J Sleep Res 1995;4:229-241
44. Gossop MR, Bradley BP, Brewis RK. Amphetamine withdrawal and sleep disturbance. Drug Alcohol Depend 1982;10:177-183
45. Lin JS, Gervasoni D, Hou Y, et al. Effects of amphetamine and modafinil on the sleep/wake cycle during experimental hypersomnia induced by sleep deprivation in the cat. J Sleep Res 2000;9:89-96
46. Myrick H, Malcolm R, Taylor B, et al. Modafinil: preclinical, clinical, and post-marketing surveillance: a review of abuse liability issues. Ann Clin Psychiatry 2004;16:101-109
47. Rush CR, Kelly TH, Hays LR, et al. Acute behavioral and physiological effects of modafinil in drug abusers. Behav Pharmacol 2002;13:105-115
48. Nishino SS, Kanbayashi TT. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005;9:269-310
49. US Food and Drug Administration, Center for Drug Evaluation and Research. Provigil (Modafinil) Tablets Approval Package. Available at: http://www.fda.gov/cder/foi/nda/98/020717A_Provigil.htm. Accessibility verified March 2, 2006
50. Mitler MM, Harsh J, Hirshkowitz M, et al. Long-term efficacy and safety of modafinil (Provigil®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med 2000;1:231-243
51. Emsellem H. Efficacy and safety profiles of modafinil maintained during long-term (40 and 88 weeks) treatment of excessive daytime sleepiness associated with narcolepsy. Neurology 2000;54(7, suppl 3):A29-A30
52. Hirshkowitz M. Long-term (136 weeks) safety and efficacy of modafinil for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep 2001;24(supplement):A329
53. Besset A, Chetrit M, Carlander B, et al. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiol Clin 1996;26:60-66
54. Reid KJ, Zee PC. Orcadian rhythm disorders. Semin Neurol 2004;24:315-325
55. Rosenberg R, Erman M, Emsellem H, et al. Modafinil improves quality of life and is well tolerated in shift work sleep disorder. Sleep 2003;26: A112-A113
56. Erman M. Patient quality of life and tolerability of long-term modafinil in shift work sleep disorder. Presented at Associated Professional Sleep Societies; June 5-10, 2004; Philadelphia, Pa
57. Collop N. Obstructive sleep apnea syndromes. Semin Respir Crit Care Med 2005;26:13-24
58. Sullivan C, Issa F, Berthon-Jones M, et al. Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1981;1:862-865
59. Krupp LB. Fatigue in multiple sclerosis: definition, pathophysiology and treatment. CNS Drugs 2003;17:225-234
60. MacAllister WS, Krupp LB. Multiple sclerosis-related fatigue. Phys Med Rehabil Clin N Am 2005;16:483-502
61. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984;65:135-138
62. Sandroni P, Walker C, Starr A. 'Fatigue' in patients with multiple sclerosis: motor pathway conduction and event-related potentials. Arch Neurol 1992;49:517-524
63. Sharma KR, Kent-Braun J, Mynhier MA, et al. Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. Muscle Nerve 1995;18:1403-1411
64. Zifko UA, Rupp M, Schwarz S, et al. Modafinil in treatment of fatigue in multiple sclerosis: results of an open-label study. J Neurol 2002;249:983-987
65. Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler 2003;9:219-227
66. Rammohan KW, Rosenberg JH, Lynn DJ, et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002;72:179-183
67. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005;64:1139-1143
68. Rye DB. Sleepiness and unintended sleep in Parkinson's disease. Curr Treat Options Neurol 2003;5:231-239
69. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol 2002;25:111-114
70. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18:287-293
71. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002;25:905-909
72. Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005;76:1636-1639
73. Reid S, Chalder T, Cleare A, et al. Chronic fatigue syndrome. BMJ 2000;320:292-296
74. Whiting P, Bagnall AM, Sowden AJ, et al. Interventions for the treatment and management of chronic fatigue syndrome: a systematic review [Erratum in JAMA 2002;287:1401]. JAMA 2001;286:1360-1368
75. Turkington D, Hedwat D, Rider I, et al. Recovery from chronic fatigue syndrome with modafinil. Hum Psychopharmacol 2004;19:63-64
76. Randall DC, Cafferty FH, Shneerson JM, et al. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. J Psychopharmacol 2005;19:647-660
77. Chan KM, Strohschein FJ, Rydz D, et al. Randomized controlled trial of modafinil for the treatment of fatigue in postpolio patients. Muscle Nerve 2006;33:138-141
78. Rabkin JG, McElhiney MC, Rabkin R, et al. Modafinil treatment for fatigue in HIV+ patients: a pilot study. J Clin Psychiatry 2004;65:1688-1695
79. Howcroft DJ, Jones RW. Does modafinil have the potential to improve disrupted sleep patterns in patients with dementia? [letter] Int J Geriatr Psychiatry 2005;20:492-495
80. Cochran JW. Effect of modafinil on fatigue associated with neurological illnesses. J Chronic Fatigue Syndrome 2001;8:65-70
81. Schaller JL, Behar D. Modafinil in fibromyalgia treatment [letter]. J Neuropsychiatry Clin Neurosci 2001;13:530-531
82. Kaplan MM, Bonis PA. Modafinil for the treatment of fatigue in primary biliary cirrhosis [letter]. Ann Intern Med 2005;143:546-547
83. Carter GT, Weiss MD, Lou JS, et al. Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care 2005;22:55-59
84. Lechin F, van der Dijs B, Pardey-Maldonado B, et al. Enhancement of noradrenergic neural transmission: an effective therapy of myasthenia gravis: a report on 52 consecutive patients. J Med 2000;31:333-361
85. Berigan T. Modafinil treatment of excessive sedation associated with divalproex sodium [letter]. Can J Psychiatry 2004;49:72-73
86. Berigan TR. Modafinil treatment of excessive daytime sedation and fatigue associated with topiramate. Prim Care Companion J Clin Psychiatry 2002;4:249-250
87. Schwartz TL, Azhar N, Cole K, et al. An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy. J Clin Psychiatry 2004;65:1223-1227
88. Sevy S, Rosenthal MH, Alvir J, et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 2005;66:839-843
89. Makela EH, Miller K, Cutlip WD II. Three case reports of modafinil use in treating sedation induced by antipsychotic medications [letter]. J Clin Psychiatry 2003;64:485-486
90. Dequardo JR. Modafinil-associated clozapine toxicity [letter]. Am J Psychiatry 2002;159:1243-1244
91. Larijani GE, Goldberg ME, Hojat M, et al. Modafinil improves recovery after general anesthesia. Anesth Analg 2004;98:976-981, table of contents
92. Bruera E, Fainsinger R, MacEachern T, et al. The use of methylphenidate in patients with incident cancer pain receiving regular opiates: a preliminary report. Pain 1992;50:75-77
93. Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med 2003;4:135-140
94. Taneja I, Bruehl S, Robertson D. Effect of modafinil on acute pain: a randomized double-blind crossover study. J Clin Pharmacol 2004;44:1425-1427
95. Centers for Disease Control and Prevention. Mental health in the United States: prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder: United States, 2003. MMWR Morb Mortal Wkly R 2005;54:842-847
96. Pary R, Lewis S, Matuschka PR, et al. Attention deficit disorder in adults. Ann Clin Psychiatry 2002;14:105-111
97. Buitelaar JK, Montgomery SA, van Zwieten-Boot BJ. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol 2003;13:297-304
98. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996;153:1147-1153
99. Kratochvil CJ, Vaughan BS, Harrington MJ, et al. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/ hyperactivity disorder. Expert Opin Pharmacother 2003;4:1165-1174
100. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Biol Psychiatry 2005;57:793-801
101. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000;10:311-320
102. Rugino TA, Samsock TC. Modafinil in children with attention-deficit hyperactivity disorder. Pediatr Neurol 2003;29:136-142
103. Turner DC, Clark L, Dowson J, et al. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 2004;55:1031-1040
104. Cephalon. Cephalon reports no benefit from PROVIGIL in study of adults with ADHD. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c= 81709&p=irol-newsArticle&ID=182727&highlight= adhd. Accessibility verified March 2, 2006
105. Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005;116:e777-e784
106. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry 2004;65(suppl 16):27-32
107. Markovitz PJ, Wagner S. An open-label trial of modafinil augmentation in patients with partial response to antidepressant therapy [letter]. J Clin Psychopharmacol 2003;23:207-209
108. Menza MA, Kaufman KR, Castellanos A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000;61:378-381
109. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005;66:85-93
110. Kaufman KR, Menza MA, Fitzsimmons A. Modafinil monotherapy in depression [case report]. Eur Psychiatry 2002;17:167-169
111. Price CS, Taylor FB. A retrospective chart review of the effects of modafinil on depression as monotherapy and as adjunctive therapy. Depress Anxiety 2005;21:149-153
112. Camacho A, Stein MB. Modafinil for social phobia and amphetamine dependence [letter]. Am J Psychiatry 2002;159:1947-1948
113. Fernandes PP, Petty F. Modafinil for remitted bipolar depression with hypersomnia. Ann Pharmacother 2003;37:1807-1809
114. Barbini B, Bertelli S, Colombo C, et al. Sleep loss, a possible factor in augmenting manic episode. Psychiatry Res 1996;65:121-125
115. Frye M, Grunze H, Suppes T, et al. Modafinil in the treatment of bipolar depression: a placebo-controlled study. Neuropsychopharmacology 2005;30(suppl 1):S111
116. Vorspan F, Warot D, Consoli A, et al. Mania in a boy treated with modafinil for narcolepsy [letter]. Am J Psychiatry 2005;162:813-814
117. Even C, Thuile J, Santos J, et al. Modafinil as an adjunctive treatment to sleep deprivation in depression [116]. J Psychiatry Neurosci 2005;30:432-433
118. Giedke H, Schwarzler F. Therapeutic use of sleep deprivation in depression. Sleep Med Rev 2002;6:361-377
119. Dackis C, O'Brien C. Glutamatergic agents for cocaine dependence. Ann N Y Acad Sci 2003;1003:328-345
120. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30:205-211
121. Rosenthal MH, Bryant SL. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin Neuropharmacol 2004;27:38-43
122. Turner DC, Clark L, Pomarol-Clotet E, et al. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004;29:1363-1373
123. Henderson DC, Louie PM, Koul P, et al. Modafinil-associated weight loss in a clozapine-treated schizoaffective disorder patient. Ann Clin Psychiatry 2005;17:95-97
124. Pierre J, Pelioan J, Wirshing D, et al. A double-blind placebo controlled trial of modafinil for negative symptoms in schizophrenia, 2005. Neuropsychopharmacology 2005;30(suppl 1):S207
125. Narendran R, Young CM, Valenti AM, et al. Is psychosis exacerbated by modafinil? [letter] Arch Gen Psychiatry 2002;59:292-293
126. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727
127. Makris AP, Rush CR, Frederich RC, et al. Wake-promoting agents with different mechanisms of action: comparison of effects of modafinil and amphetamine on food intake and cardiovascular activity. Appetite 2004;42:185-195
128. Hurst DL, Lajara-Nanson W. Use of modafinil in spastic cerebral palsy. J Child Neurol 2002;17:169-172
129. Hurst DL, Lajara-Nanson WA, Dinakar P, et al. Retrospective review of modafinil use for cerebral palsy. J Child Neurol 2004;19:948-951
130. ESPN. Official Suggests Modafinil, THG Abuse Related. Available at: http://espn.go.com/oly/news/2003/1027/1648385.html. Accessibility verified March 2, 2006
131. Kaufman KR. Modafinil in sports: ethical considerations. Br J Sports Med 2005;39:241-244
132. World Anti-Doping Agency. The 2005 Prohibited List: International Standard. Available at: http://www.wada-ama.org/rtecontent/document/list_2005. pdf. Accessibility verified March 2, 2006
133. American Medical News. Type A's Perk Up Over Modafinil, an Anti-Sleeping Pill. Available at: http://www.ama-assn.org/amednews/2002/11/11/h1121111.htm. Accessibility verified March 2, 2006
134. Randall DC, Fleck NL, Shneerson JM, et al. The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers. Pharmacol Biochem Behav 2004;77:547-555
135. Rush CR, Kelly TH, Hays LR, et al. Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug Alcohol Depend 2002;67:311-322
136. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14:53-60
137. Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000;23:149-156
138. Cephalon. 2003 Annual Report. Available at: http://media.corporate-ir. net/media_files/irol/81/81709/reports/2003ar.pdf. Accessibility verified March 2, 2006
139. Wesensten NJ, Belenky G, Kautz MA, et al. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology (Berl) 2002;159:238-247
140. Swanson JM, Boellner S, Rugino T, et al. Pediatric formulation of modafinil effective in children and adolescents with ADHD. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
141. Greenhill L. Modafinil film-coated tablets significantly improve symptoms of attention deficit/hyperactivity disorder in children and adolescents at school and home and overall clinical condition. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit; June 6-9, 2005; Boca Raton, Fla
142. Biederman J. Modafinil pediatric formulation has early and sustained effect in ADHD. Presented at the 158th annual meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, Ga
143. Swanson J. Modafinil film-coated tablets demonstrate early efficacy in pediatric attention-deficit/hyperactivity disorder and are not associated with withdrawal or discontinuation syndrome. Presented at the 45th annual meeting of the New Clinical Drug Evaluation Unit; June 6-9, 2005; Boca Raton, Fia
144. Cephalon. Cephalon Files New Drug Application for NUVIGIL™. Available at: http://phx.corporate-ir.net/phoenix.zhtml?c=81709& p=irol-newsArticle&ID=690724&highlight=nuvigil. Accessibility verified March 2, 2006
145. Schwartz JR. Pharmacologic management of daytime sleepiness. J Clin Psychiatry 2004;65(suppl 16):46-49
146. Dackis CA, Lynch KG, Yu E, et al. Modafinil and cocaine; a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 2003;70:29-37